Dengue research opportunities in the Americas.
Dengue is a systemic arthropod-borne viral disease of major global public health importance. At least 2.5 billion people who live in areas of the world where dengue occurs are at risk of developing dengue fever (DF) and its severe complications, dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Repeated reemergences of dengue in sudden explosive epidemics often cause public alarm and seriously stress healthcare systems. The control of dengue is further challenged by the lack of effective therapies, vaccines, and point-of-care diagnostics. Despite years of study, even its pathogenic mechanisms are poorly understood. This article discusses recent advances in dengue research and identifies challenging gaps in research on dengue clinical evaluation, diagnostics, epidemiology, immunology, therapeutics, vaccinology/clinical trials research, vector biology, and vector ecology. Although dengue is a major global tropical pathogen, epidemiologic and disease control considerations in this article emphasize dengue in the Americas.
Virology Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-6603, USA. claughlin@niaid.nih.gov
Catherine A
CA
Laughlin
David M
DM
Morens
M Cristina
MC
Cassetti
Adriana
A
Costero-Saint Denis
Jose-Luis
JL
San Martin
Stephen S
SS
Whitehead
Anthony S
AS
Fauci
D000569:Americas / Q000453:epidemiology; D000818:Animals; D000852:Anopheles / Q000821:virology; D002986:Clinical Trials as Topic; D003715:Dengue / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control / Q000821:virology*; D053059:Dengue Vaccines / Q000276:immunology; D003716:Dengue Virus / Q000276:immunology / Q000502:physiology; D019353:Endemic Diseases / Q000517:prevention & control*; D006801:Humans; D007303:Insect Vectors / Q000821:virology
D053059:Dengue Vaccines